Business
New Manufacturing Process Patent for Ox-1
TheraCryf plc has filed a new process patent for its lead asset, Ox-1, a selective orexin-1 receptor antagonist for addiction, which, if granted, could extend commercial exclusivity to 2046, significantly beyond the existing composition of matter patent. This filing follows successful manufacturing optimization and scale-up, identifying novel efficiency improvements. Process patents create an additional barrier to generic competition by requiring alternative manufacturing routes to avoid infringement, strengthening the company's intellectual property estate as the program advances towards clinical readiness later in 2026. This strategic move aims to maximize the long-term commercial value and partnering potential of the Ox-1 program. Disclaimer*
About this update from Theracryf Plc
16 April 2026 TheraCryf plc ("TheraCryf", the "Company" or the "Group") New Manufacturing Process Patent Extends Exclusivity for Lead Asset Ox-1 Additional patent submission provides potential 20-year protection Strengthens long-term commercial value and partnering potential TheraCryf plc (AIM: TCF), the biotech company developing new medicines for addiction and other neuropsychiatric disorders, today announces that it has filed a new process patent covering novel aspects of the manufacturing method for its lead programme, a selective orexin-1 receptor antagonist (Ox-1) being developed for addiction. The patent, when granted, will protect for 20 years from filing, potentially to 2046, extends the commercial exclusivity for the Ox-1 blocker across major markets, substantially beyond the life of the existing global Composition of Matter patent. The filing follows recent successful manufacturing optimisation and scale-up work during which several novel and efficiency-enhancing chemical process improvements were identified. Process patents provide an additional barrier to generic competition, as alternative manufacturing routes must be developed to avoid infringement, which are typically not undertaken by competitors. The filing builds on the Company's recently announced strengthening of the Ox-1 patent estate across key global markets and forms part of its broader strategy to establish a robust intellectual property portfolio as the programme advances towards completing the data required for clinical readiness later in 2026. Dr Huw Jones, Chief Executive Officer of TheraCryf, commented: "This new process patent submission further strengthens the intellectual property protection surrounding our lead asset and has the potential to extend its commercial exclusivity very substantially. As TheraCryf progresses swiftly towards clinical development, expanding our broad and defensible patent portfolio is central to maximising the long-term commercial value of the programme and its attractiveness to potential partners." -Ends- Enquiries TheraCryf plc Dr Huw Jones, CEO Toni Hänninen, CFO Dr Helen Kuhlman, COO +44 (0)1625 315 090 [email protected] Singer Capital Markets (NOMAD & Joint Broker) Phil Davies / Patrick Weaver +44 (0)20 7496 3000 Turner Pope Investments (Join...